|
|
Volumn 355, Issue 6330, 2017, Pages 1109-1110
|
|
iPS cell therapy reported safe
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CELLS AND CELL COMPONENTS;
DEVELOPMENTAL BIOLOGY;
EYE;
HISTOLOGY;
INDUCED RESPONSE;
RESEARCH WORK;
AGE RELATED MACULAR DEGENERATION;
ARTICLE;
BLINDNESS;
CARDIAC MUSCLE CELL;
HAPLOTYPE;
HEART FAILURE;
HLA MATCHING;
HUMAN;
HUMAN EMBRYONIC STEM CELL;
INDUCED PLURIPOTENT STEM CELL;
NANOTECHNOLOGY;
OPHTHALMOLOGIST;
PARKINSON DISEASE;
PRIORITY JOURNAL;
RETINA CELL;
SAFETY;
SOMATIC CELL THERAPY;
STEM CELL TRANSPLANTATION;
TREATMENT OUTCOME;
ANIMAL;
BIOLOGICAL THERAPY;
MACULAR DEGENERATION;
REGENERATIVE MEDICINE;
TRANSPLANTATION;
TRENDS;
AUSTRALIA;
MELBOURNE;
VICTORIA [AUSTRALIA];
IPS;
ANIMALS;
CELL- AND TISSUE-BASED THERAPY;
HUMANS;
INDUCED PLURIPOTENT STEM CELLS;
MACULAR DEGENERATION;
REGENERATIVE MEDICINE;
|
|
EID: 85015155107
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.355.6330.1109 Document Type: Article |
|
Times cited : (12)
|
|
References (0)
|